These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 33046132)

  • 1. The urgent need to empower rare disease organizations in China: an interview-based study.
    Li X; Lu Z; Zhang J; Zhang X; Zhang S; Zhou J; Li B; Ou L
    Orphanet J Rare Dis; 2020 Oct; 15(1):282. PubMed ID: 33046132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A questionnaire-based study to comprehensively assess the status quo of rare disease patients and care-givers in China.
    Li X; Liu M; Lin J; Li B; Zhang X; Zhang S; Lu Z; Zhang J; Zhou J; Ou L
    Orphanet J Rare Dis; 2021 Jul; 16(1):327. PubMed ID: 34294091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of the rare disease and Orphan Drug Act in Taiwan.
    Hsiang NC; Huang WF; Gau CS; Tsai TW; Chang LC
    J Food Drug Anal; 2021 Dec; 29(4):717-725. PubMed ID: 35649145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study.
    Choudhury MC; Saberwal G
    Orphanet J Rare Dis; 2019 Nov; 14(1):241. PubMed ID: 31684990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of 11 national policies for rare diseases in the context of key patient needs.
    Dharssi S; Wong-Rieger D; Harold M; Terry S
    Orphanet J Rare Dis; 2017 Mar; 12(1):63. PubMed ID: 28359278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rare disease awareness and perspectives of physicians in China: a questionnaire-based study.
    Li X; Zhang X; Zhang S; Lu Z; Zhang J; Zhou J; Li B; Ou L
    Orphanet J Rare Dis; 2021 Apr; 16(1):171. PubMed ID: 33849615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of patient organizations in the rare disease ecosystem in India: an interview based study.
    Choudhury MC; Saberwal G
    Orphanet J Rare Dis; 2019 May; 14(1):117. PubMed ID: 31142331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intractable and rare diseases research in Asia.
    Song P; Gao J; Inagaki Y; Kokudo N; Tang W
    Biosci Trends; 2012 Apr; 6(2):48-51. PubMed ID: 22621985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications.
    Zhao Z; Pei Z; Hu A; Zhang Y; Chen J
    Orphanet J Rare Dis; 2023 Jul; 18(1):220. PubMed ID: 37501126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status and trend of clinical development of orphan drugs in China.
    Xiang Z; Jiang W; Yan B; Jiang J; Zheng H
    Orphanet J Rare Dis; 2022 Jul; 17(1):294. PubMed ID: 35897012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How Far Have We Come? Challenges to Orphan Drug Access in China, 2011-2017.
    Guan X; Zhang J; Man C; Ni B; Shi L
    J Pharm Sci; 2019 Jun; 108(6):2199-2205. PubMed ID: 30677418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The availability and affordability of orphan drugs for rare diseases in China.
    Gong S; Wang Y; Pan X; Zhang L; Huang R; Chen X; Hu J; Xu Y; Jin S
    Orphanet J Rare Dis; 2016 Feb; 11():20. PubMed ID: 26920579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Towards government-funded special biomedical research programs to combat rare diseases in China.
    Chen K; Yao L; Liu Z
    Biosci Trends; 2015 Apr; 9(2):88-90. PubMed ID: 25902953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is sub-national healthcare social protection sufficient for protecting rare disease patients? the case of China.
    Xu J; Yu M; Zhang Z; Gong S; Li B
    Front Public Health; 2023; 11():1198368. PubMed ID: 37397721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
    Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rare Diseases and Orphan Drugs Accessibility in Bosnia and Herzegovina.
    Guzvic V; Stojakovic N; Jusufovic R; Catic T
    Mater Sociomed; 2018 Dec; 30(4):297-303. PubMed ID: 30936797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orphan drug development in China - Turning challenges into opportunities.
    Jin X; Chen L
    Intractable Rare Dis Res; 2016 Nov; 5(4):308-313. PubMed ID: 27904831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [RARE DISEASES DTC: DIAGNOSIS, TREATMENT AND CARE].
    Mendlovic J; Barash H; Yardeni H; Banet-Levi Y; Yonath H; Raas-Rothschild A
    Harefuah; 2016 Apr; 155(4):241-4, 253. PubMed ID: 27323543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges in orphan drug development and regulatory policy in China.
    Cheng A; Xie Z
    Orphanet J Rare Dis; 2017 Jan; 12(1):13. PubMed ID: 28100254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.